Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin
Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Key facts
- Where
- A Coruna, Almería, Barcelona, Castilleja De La Cuesta, Ferrol, Palma, Pozuelo de Alarcón, Santander, and Sevilla, SpainSee the 10 sites
- Phase
- Phase 3
Where in Spain
- Instituto Medico Quirurgico San Rafael S.A.A Coruna, SpainTaking people
- Hospital Universitario TorrecárdenasAlmería, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Nisa Sevilla AljarafeCastilleja De La Cuesta, SpainTaking people
- Instituto Gallego de Cirugía OcularFerrol, SpainTaking people
- Clinica Juaneda S.A.Palma, SpainTaking people
- Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Hospital Quironsalud Infanta LuisaSevilla, SpainTaking people
- Nuevas Tecnologias En Diabetes Y En Endocrinologia S.L. ProfesionalSevilla, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07392190EU 2025-523659-73-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion: Are on stable incretin therapy at screening; With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes; Have a stable body weight (<5% body weight change) at screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.